Allo CD7 CAR WU-CART-007

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”).  WU-CART-007 uses immune cells, called T cells, that are genetically changed to identify cancer cells. In this study, T cells are collected from a healthy human donor and have been modified in a laboratory. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill those cancer cells.

Patients with T-cell Acute Lymphoblatic Leukemia (T-ALL) or Lymphoblastic Lymphoma (LBL), where the disease has come back (relapsed) or has not responded to treatment (refractory) may be eligible for the study.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at leibfreidb [at] chop.edu or 267-242-5953.

Eligibility & Criteria

IRB #:
21-019423
Official Title:
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Study Phase:
Phase I
Phase II
Eligible Age Range:
12 - 30 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in the research you will:

  • Receive a study drug WU-CART-007
  • Avoid taking certain medications (steroids, chemotherapy agents)
  • Stay in the hospital for at least 7 days after receiving the study drug
  • Complete follow up visits
  • Have research blood samples drawn